Monkeypox virus (MPXV), which causes disease in humans, has for many years been
restricted to the African continent, with only a handful of sporadic cases in other parts of the …

Monkeypox is a rare disease but is increasing in incidence in different countries since the
first case was diagnosed in the UK by the United Kingdom (UK) Health Security Agency on 6 …

Background rVSV-ZEBOV is a recombinant, replication competent vesicular stomatitis virus-
based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus. We tested …

Background A recombinant, replication-competent vesicular stomatitis virus-based vaccine
expressing a surface glycoprotein of Zaire Ebolavirus (rVSV-ZEBOV) is a promising Ebola …

Cluster Randomised Trials, Second Edition discusses the design, conduct, and analysis of
trials that randomise groups of individuals to different treatments. It explores the advantages …

Despite continued efforts to improve health systems worldwide, emerging pathogen
epidemics remain a major public health concern. Effective response to such outbreaks relies …

In 2004, Murray et al. reviewed methodological developments in the design and analysis of
group-randomized trials (GRTs). We have highlighted the developments of the past 13 years …

After decades of declining mumps incidence amid widespread vaccination, the United
States and other developed countries have experienced a resurgence in mumps cases over …

Background Nonlive vaccine approaches that are simple to deliver and stable at room
temperature or 2–8° C could be advantageous in controlling future Ebola virus (EBOV) …

Summary Background The 2014 Zaire Ebola virus outbreak highlighted the need for a safe,
effective vaccine with a rapid onset of protection. We report the safety and immunogenicity of …